{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:11:28Z","timestamp":1783635088279,"version":"3.55.0"},"reference-count":32,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:p>Context: Approximately 10% of pheochromocytomas are malignant with a 5-yr survival rate of less than 40%. Promising results have been published on single high-dosage [131I]metaiodobenzylguanidine ([131I]MIBG) treatment for malignant pheochromocytoma. We present our experience with multiple intermediate-dosage [131I]MIBG therapy instead of single high-dosage therapy.<\/jats:p>\n               <jats:p>Setting and Patients: The study took place at University Medical Centers and included two patients (one male, 36 yr of age, and one female, 43 yr of age) with widely spread metastatic pheochromocytoma and bad prognosis because of liver and lung metastases.<\/jats:p>\n               <jats:p>Interventions: Instead of a single high dosage, these two patients were treated with multiple intermediate dosages of [131I]MIBG. The first patient received 37 GBq (1 Ci) [131I]MIBG in five sessions [7400 MBq (200 mCi) each; interval range, 2\u201311 months]; the second patient received 66.6 GBq (1.8 Ci) [131I]MIBG in 12 sessions [5550 MBq (150 mCi) each; interval range, 2\u201314 months].<\/jats:p>\n               <jats:p>Outcome Measures: We measured efficacy, toxicity, and survival.<\/jats:p>\n               <jats:p>Results: Both patients had a complete symptomatic response and a partial tumor volume response. The first patient had a partial biochemical response, the second a complete biochemical response. In both cases, toxicity has been confined to nausea during treatment. Hematological toxicity was minimal, and both patients stayed euthyroid. The survival (so far) of these patients was 5 yr (clinical case 1) and 16 yr (clinical case 2) after initial diagnosis.<\/jats:p>\n               <jats:p>Conclusions: Repeated intermediate-dosage [131I]MIBG treatment appears to be a reliable and well-tolerated radionuclide therapy and might be a useful adjunct in patients with malignant pheochromocytoma, providing longstanding palliation and prolonged survival.<\/jats:p>","DOI":"10.1210\/jc.2004-2290","type":"journal-article","created":{"date-parts":[[2005,10,5]],"date-time":"2005-10-05T22:02:56Z","timestamp":1128549776000},"page":"5888-5895","source":"Crossref","is-referenced-by-count":23,"title":["Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma"],"prefix":"10.1210","volume":"90","author":[{"given":"Marnix G. E. H.","family":"Lam","sequence":"first","affiliation":[{"name":"Departments of Nuclear Medicine (M.G.E.H.L., P.P.v.R., J.M.H.d.K.), 3508 GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. M.","family":"Lips","sequence":"additional","affiliation":[{"name":"Endocrinology (C.J.M.L.), 3508 GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter L.","family":"Jager","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine (P.L.J.), Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P. F.","family":"Dullaart","sequence":"additional","affiliation":[{"name":"Endocrinology (R.P.F.D.), AZG, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eef G. W. M.","family":"Lentjes","sequence":"additional","affiliation":[{"name":"Clinical Laboratory (E.G.W.M.L.), University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"van Rijk","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine (M.G.E.H.L., P.P.v.R., J.M.H.d.K.), 3508 GA Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M. H.","family":"de Klerk","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine (M.G.E.H.L., P.P.v.R., J.M.H.d.K.), 3508 GA Utrecht, The Netherlands"},{"name":"Department of Nuclear Medicine (J.M.H.d.K.), Meander Medical Center, Amersfoort, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071617480605500_R1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.0954-6820.1988.tb15883.x","article-title":"Long-term results in 64 patients operated upon for pheochromocytoma.","volume":"223","author":"Stenstrom","year":"1988","journal-title":"Acta Med Scand"},{"key":"2020071617480605500_R2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF03345808","article-title":"Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990.","volume":"15","author":"Mornex","year":"1992","journal-title":"J Endocrinol Invest"},{"key":"2020071617480605500_R3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s004020100305","article-title":"Twenty-six-years\u2019 survival with multiple bone metastasis of malignant pheochromocytoma.","volume":"121","author":"Yoshida","year":"2001","journal-title":"Arch Orthop Trauma Surg"},{"key":"2020071617480605500_R4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.1997.00440290087009","article-title":"Metyrosine and pheo*chromocytoma.","volume":"157","author":"Steinsapir","year":"1997","journal-title":"Arch Intern Med"},{"key":"2020071617480605500_R5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2265.2001.01396.x","article-title":"The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.","volume":"55","author":"Kaltsas","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480605500_R6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00000421-199908000-00008","article-title":"Treatment of malignant pheochromocytomas with 131I metaiodobenzylguanidine and chemotherapy.","volume":"22","author":"Sisson","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"2020071617480605500_R7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"2020071617480605500_R8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6601276","article-title":"Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.","volume":"89","author":"Kolby","year":"2003","journal-title":"Br J Cancer"},{"key":"2020071617480605500_R9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","article-title":"High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.","volume":"98","author":"Rose","year":"2003","journal-title":"Cancer"},{"key":"2020071617480605500_R10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","article-title":"Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.","volume":"134","author":"Safford","year":"2003","journal-title":"Surgery"},{"key":"2020071617480605500_R11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"2020071617480605500_R12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine [131I-mIBG].","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480605500_R13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/ejso.2001.1225","article-title":"[131I]MIBG radionuclide therapy in carcinoid syndrome.","volume":"28","author":"Taal","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"2020071617480605500_R14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.1998.16.1.229","article-title":"Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.","volume":"16","author":"Matthay","year":"1998","journal-title":"J Clin Oncol"},{"key":"2020071617480605500_R15","first-page":"3920","article-title":"Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one.","volume":"47","author":"Jaques Jr","year":"1987","journal-title":"Cancer Res"},{"key":"2020071617480605500_R16","first-page":"1620","article-title":"Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function.","volume":"28","author":"Sisson","year":"1987","journal-title":"J Nucl Med"},{"key":"2020071617480605500_R17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM198107023050103","article-title":"Scintigraphic localization of pheochromocytoma.","volume":"305","author":"Sisson","year":"1981","journal-title":"N Engl J Med"},{"key":"2020071617480605500_R18","first-page":"197","article-title":"Radiopharmaceutical treatment of malignant pheochromocytoma.","volume":"25","author":"Sisson","year":"1984","journal-title":"J Nucl Med"},{"key":"2020071617480605500_R19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment.","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"2020071617480605500_R20"},{"key":"2020071617480605500_R21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2214\/ajr.115.4.783","article-title":"The roentgenologic aspects of metastatic pheochromocytoma.","volume":"115","author":"James","year":"1972","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"2020071617480605500_R22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00000658-197405000-00029","article-title":"Current management of pheochromocytoma.","volume":"179","author":"Remine","year":"1974","journal-title":"Ann Surg"},{"key":"2020071617480605500_R23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0936-6555(02)00273-X","article-title":"Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.","volume":"15","author":"Bomanji","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2020071617480605500_R24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2004-1500","article-title":"High frequency of bone\/bone marrow involvement in advanced medullary thyroid cancer.","volume":"90","author":"Mirallie","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480605500_R25","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1210\/jcem.83.6.4870","article-title":"Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors.","volume":"83","author":"Eisenhofer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480605500_R26","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1210\/jc.2003-030235","article-title":"Superiority of 6-[18F]fluorodopamine positron emission tomography versus [131I]metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.","volume":"88","author":"Ilias","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480605500_R27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1210\/jc.2003-031091","article-title":"Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma.","volume":"89","author":"Ilias","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480605500_R28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1196\/annals.1296.061","article-title":"Anatomical and functional imaging of metastatic pheochromocytoma.","volume":"1018","author":"Ilias","year":"2004","journal-title":"Ann NY Acad Sci"},{"key":"2020071617480605500_R29","first-page":"685","article-title":"[123I]Metaiodobenzylguanidine and [111In]octreotide uptake in benign and malignant pheochromocytomas.","volume":"86","author":"Harst","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617480605500_R30","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/archinte.160.16.2521","article-title":"Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice.","volume":"160","author":"Witteles","year":"2000","journal-title":"Arch Intern Med"},{"key":"2020071617480605500_R31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2265.2004.02077.x","article-title":"Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma?","volume":"61","author":"Taieb","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071617480605500_R32","first-page":"3641","article-title":"A \u201cpheo\u201d lurks: novel approaches for locating occult pheochromocytoma.","volume":"86","author":"Pacak","year":"2001","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/10\/5888\/10777257\/jcem5888.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/10\/5888\/10777257\/jcem5888.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:39:13Z","timestamp":1594957153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/90\/10\/5888\/2839840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2004-2290","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}